Research and Markets: Women's Health Therapeutics, Analysis and Market Forecasts to 2016

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/61183d/womens_health_the) has announced the addition of the "Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets" report to their offering.

“Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets”

Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Women's Health (WH) market. The report analyzes the markets for WH disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Global WH Disorder Therapeutics Market is Forecast to Grow Rapidly from 2009 to 2016

In 2009, the global women's health (WH) disorder therapeutics market was estimated to be worth $12.1 billion, after having had a Compound Annual Growth Rate (CAGR) of 2.6% between 2001 and 2009. By 2016, the global WH disorder therapeutics market is estimated to reach $22 billion, indicating a CAGR of 8.8% between 2009 and 2016. Owing to several factors, such as the publication of the Women's Health Initiative (WHI) study results, a lack of effective therapeutics, the WH disorder therapeutics market grew moderately between 2001 and 2009. However, the launch of novel therapeutics in the near future is expected to satisfy the unmet need in the market. This will have a pronounced effect on the menopause therapeutics market.

The current WH disorder therapeutics pipeline is promising with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq, Aprela, Menerba, Elagolix and Cetrorelix. In addition, the recent launch of potential blockbuster drugs such as Prolia (Denosumab) for the treatment of postmenopausal osteoporosis will nullify the effect of major drugs such as Fosamax, Boniva and Actonel losing their patents. Thus, the WH disorder therapeutics market is an attractive market with huge opportunities for novel entrants with high safety and efficacy profiles.

Scope

The scope of this report includes:

Annualized market data for the women's health market from 2001 to 2009, forecast forward to 2016.
Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, women's infertility and polycistic ovarian syndrome.
Analysis of the women's health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
Market characterization of the women's health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
Key drivers and barriers that have a significant impact on the market.
Coverage of pipeline molecules in various phases of drug development.
Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.
Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
Develop key strategic initiatives by understanding the key focus areas of leading companies.
Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Key Topics Covered:

1 List of Tables and Figures

2 Global WH Disorder Therapeutics Market:Introduction

3 Global WH Disorder Therapeutics Market: Market Characterization

4 Global WH Disorder Therapeutics Market: Therapeutic Landscape

5 Global WH Disorder Therapeutics Market: Geographical Landscape

6 Global WH Disorder Therapeutics Market: Pipeline Analysis

7 Global WH Disorder Therapeutics Market: Competitive Landscape

8 Global WH Disorder Therapeutics Market: Strategic Consolidations

9 Global WH Disorder Therapeutics Market: Appendix

Companies Mentioned: